Metastatic Bone Disease Market Report 2026

The metastatic bone disease market size has grown strongly in recent years. It will grow from $18.82 billion in 2025 to $20.68 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to increasing cancer incidence, growing cases of bone metastasis, expanding chemotherapy usage, development of radiation therapy techniques, rising use of bisphosphonates.

The metastatic bone disease market size is expected to see strong growth in the next few years. It will grow to $28.84 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to growth in targeted bone agents, rising adoption of immunotherapy combinations, increasing demand for non-invasive tumor ablation, expansion of personalized treatment approaches, strengthening oncologic diagnostic capabilities. Major trends in the forecast period include advancements in targeted bone metastasis therapies, AI-assisted diagnostic imaging enhancement, digital platforms for remote symptom monitoring, automation in oncology radiology workflows, virtual reality-based surgical and treatment training.

The rising incidence of bone cancer is expected to drive the growth of the metastatic bone disease market in the coming years. Bone cancer is a malignant tumor that originates in bone cells. Its prevalence is influenced by genetic predisposition, radiation exposure, and environmental factors such as contact with certain chemicals. Bone cancer can result in metastatic bone disease when cancer cells from the primary tumor spread through the bloodstream or lymphatic system, establishing new tumors in other bones. For example, in 2023, the American Cancer Society, a US-based non-profit organization, reported 3,970 new cases of bone and joint cancer, an increase from the 3,910 cases recorded in 2022. Consequently, the growing prevalence of bone cancer is contributing to the expansion of the metastatic bone disease market.

Key players in the metastatic bone disease market are concentrating on developing biosimilar therapies to enhance patient access and lower treatment costs while ensuring clinical effectiveness. Biosimilars are biologic medical products that closely resemble already approved reference drugs, with no clinically meaningful differences in safety or efficacy. For example, in March 2024, Sandoz, a Switzerland-based biopharmaceutical firm, obtained FDA approval for Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz), the first and only FDA-approved biosimilars of denosumab for all indications of the reference products. These indications include preventing skeletal-related events in patients with bone metastases from solid tumors. Such developments are expected to improve treatment accessibility and clinical outcomes for individuals with metastatic bone disease.

In May 2024, Telix Pharmaceuticals Limited, an Australia-based biopharmaceutical company, completed the acquisition of QSAM Biosciences for an undisclosed sum. The acquisition is intended to enhance Telix's therapeutic pipeline, reinforcing its expertise in radiopharmaceutical innovation and expanding its focus on oncology and rare diseases. Through this agreement, Telix aims to expedite the development and delivery of treatments for bone metastases, seeking to offer meaningful benefits to affected patients. QSAM Biosciences Inc. is a US-based company focused on developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer.

Major companies operating in the metastatic bone disease market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Medtronic plc, Eli Lilly and Company, Amgen Inc., Boston Scientific Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Jazz Pharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Mylan N.V., Novocure GmbH, Galapagos NV, Telix Pharmaceuticals Limited.

North America was the largest region in the metastatic bone disease market in 2025. The regions covered in the metastatic bone disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the metastatic bone disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on medical devices, oncology drugs, and radiology equipment have increased treatment costs and slowed supply chains, particularly affecting regions reliant on imported therapies such as Asia-Pacific and Latin America. Medication categories like bisphosphonates, targeted biologics, and radiation equipment face price pressures, limiting accessibility. Despite these challenges, tariffs have encouraged domestic manufacturing and accelerated investment in local production facilities, potentially improving long-term treatment availability and cost efficiency.

The metastatic bone disease market research report is one of a series of new reports that provides metastatic bone disease market statistics, including metastatic bone disease industry global market size, regional shares, competitors with a metastatic bone disease market share, detailed metastatic bone disease market segments, market trends and opportunities, and any further data you may need to thrive in the metastatic bone disease industry. This metastatic bone disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Metastatic bone disease is a condition in which cancer cells spread from their original (primary) site to the bones, leading to weakened bones and causing symptoms such as pain, fractures, spinal cord compression, and hypercalcemia. The presence of metastatic bone disease indicates that the cancer has advanced and becomes more challenging to treat.

The primary treatments for metastatic bone disease include medication, radiation therapy, surgical intervention, and tumor ablation therapy. Medication involves pharmaceutical drugs used to alleviate symptoms, slow disease progression, or address the underlying causes of bone metastases. These cancers commonly originate from the breast, lung, thyroid, kidney, prostate, and other organs. The main end-users of these treatments include hospitals, specialty clinics, and ambulatory surgical centers.

The metastatic bone disease market consists of revenues earned by entities by providing services such as chemotherapy, hormone therapy, bisphosphonates, opiate therapy, and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The metastatic bone disease market includes sales of intramedullary rods, plates and screws, prosthetic devices, spinal instrumentation, and radiation therapy accessories. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.